Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(KU 0063794; KU0063794)
KU-0063794 Chemical Structure
|Product name: KU-0063794|
|Cat. No.: HY-50710|
KU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively); no effect on PI3Ks.
IC50 value: ~10 nM 
KU-0063794 displays no activity at PI 3-kinase or 76 other kinases tested. Inhibits activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK. KU-0063794 suppresses cell growth and induces G1 cell cycle arrest in vitro.
|M.Wt||465.54||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO ≥10mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL
|1 mg||5 mg||10 mg|
|1 mM||2.1480 mL||10.7402 mL||21.4804 mL|
|5 mM||0.4296 mL||2.1480 mL||4.2961 mL|
|10 mM||0.2148 mL||1.0740 mL||2.1480 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|KU-0063794||Queen Mary University of London||Metastatic renal cancer||28-FEB-13||31-DEC-15||Phase 2||15-NOV-13|
|AstraZeneca plc||Advanced solid tumor||31-DEC-09||28-FEB-14||Phase 1||06-NOV-13|
|AstraZeneca plc||Metastatic breast cancer||31-MAY-12||30-NOV-13||Phase 1||01-NOV-13|
. Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B.Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.J Biol Chem. 2012 Jul 6;287(28):23698-709. Epub 2012 May 22.
. Wahdan-Alaswad RS, Bane KL, Song K, Shola DT, Garcia JA, Danielpour D.Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.Mol Cancer Res. 2012 Jun;10(6):821-33. Epub 2012 Mar 27.
AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM with excellent selectivity (～1,000-fold) against PI3K isoforms and ATM/DNA-PK.
AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms ((alpha)/(beta)/(gamma)/(delta)).
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K(alpha) (IC50=4 (mu)M).
Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin.
ETP-46464 is a cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-K(alpha), and ATM (IC50= 0.6, 14, 36, 170, and 545 nM, respectively).
Everolimus (RAD001) is a mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.
GDC-0084 is a potent, selective inhibitor of Class I PI3K and mTOR with good penetration across the blood-brain barrier.
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM; >700-fold selectivity over PI3K(alpha) and other 266 kinases.
GDC-0980 (RG7422) is a potent, class I PI3K inhibitor for PI3K(alpha)/(beta)/(delta)/(gamma) with IC50 of 5 nM/27 nM/7 nM/14 nM, respectively; also a mTOR inhibitor with Ki of 17 nM, and highly selective versus others PIKK family kinases.
GNE-317 is a potent PI3K/mTOR inhibitor that can cross the blood–brain barrier; shows potent suppression of the PI3K pathway in the brain of mice with intact BBB.